Chicago Equity Partners LLC lowered its position in shares of Humana Inc (NYSE:HUM) by 67.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,470 shares of the insurance provider’s stock after selling 13,528 shares during the period. Chicago Equity Partners LLC’s holdings in Humana were worth $1,716,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Janney Montgomery Scott LLC grew its stake in shares of Humana by 3.5% during the second quarter. Janney Montgomery Scott LLC now owns 2,871 shares of the insurance provider’s stock worth $762,000 after purchasing an additional 98 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Humana in the second quarter valued at $185,000. World Asset Management Inc boosted its stake in Humana by 10.9% in the first quarter. World Asset Management Inc now owns 10,840 shares of the insurance provider’s stock valued at $2,883,000 after acquiring an additional 1,067 shares in the last quarter. Stoneridge Investment Partners LLC boosted its stake in Humana by 19.8% in the first quarter. Stoneridge Investment Partners LLC now owns 3,826 shares of the insurance provider’s stock valued at $1,018,000 after acquiring an additional 632 shares in the last quarter. Finally, Advisor Group Inc. boosted its stake in Humana by 8.3% in the second quarter. Advisor Group Inc. now owns 4,913 shares of the insurance provider’s stock valued at $1,303,000 after acquiring an additional 377 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.
Several research firms have issued reports on HUM. UBS Group upped their price objective on shares of Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. SunTrust Banks upped their price objective on shares of Humana to $340.00 and gave the company a “hold” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. upped their price objective on shares of Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Piper Jaffray Companies upped their price objective on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Deutsche Bank began coverage on shares of Humana in a research note on Thursday. They issued a “hold” rating for the company. Two analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the stock. Humana presently has an average rating of “Buy” and a consensus price target of $341.95.
In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.54% of the company’s stock.
Shares of HUM opened at $274.69 on Friday. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The company has a market capitalization of $37.40 billion, a price-to-earnings ratio of 18.88, a price-to-earnings-growth ratio of 1.20 and a beta of 0.84. The firm has a 50-day simple moving average of $287.14 and a 200-day simple moving average of $269.22. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.25 billion during the quarter, compared to the consensus estimate of $15.88 billion. During the same quarter in the prior year, the firm earned $3.96 earnings per share. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. Equities research analysts forecast that Humana Inc will post 17.63 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, September 27th. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. Humana’s dividend payout ratio (DPR) is 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: How to track put option volume
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.